Post-earnings recap
Reported
Thu, May 8, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a wider-than-expected loss per share, which contributed to a significant drop in stock price by 9.28%. The lack of revenue figures and guidance updates left investors uncertain about the company's future performance. Management's defensive commentary indicates they are facing challenges but remain committed to their pipeline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.55 | N/A | +31.08% |
| Revenue | N/A | N/A | N/A |
Management expressed a defensive tone regarding current market conditions. They emphasized their focus on pipeline advancement despite challenges.
We are focused on advancing our pipeline despite the current challenges.
Our commitment to innovation remains strong as we navigate these market conditions.